Showing results (861-870 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|March 26, 2021
Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancerNurul A Abdullah, Martyn Inman, Christopher J Moody, et al.
Investigational New Drugs|March 26, 2021
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trialAndrew W Hahn, Jad Chahoud, Matthew T Campbell, et al.
Investigational New Drugs|April 26, 2023
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinomaShiqi Hu, Yaqin Liu, Qidong Yang, et al.
Investigational New Drugs|January 1, 1986
High dose AZQ in renal cancer. A Southwest Oncology Group phase II studyR L Stephens, R Kirby, E D Crawford, et al.
Investigational New Drugs|March 31, 2021
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cellsJinbing Xue, Gang Wu, Umer Ejaz, et al.
Investigational New Drugs|March 29, 2023
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokinesSiqi Shang, Yunshuo Chen, Xuejiao Yang, et al.
Investigational New Drugs|January 15, 2014
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancerNeelesh Sharma, Nathan Pennell, Myles Nickolich, et al.
Investigational New Drugs|November 10, 2025
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitorsHoi Wai Chan, Chris Chun Long Tse, Yu-Chung Li, et al.
Investigational New Drugs|October 22, 2025
The role of dinutuximab beta with beta cell function, apoptosis, and proliferation: new approaches to proteomic analysis of insulinomaAyse Karatug Kacar
Investigational New Drugs|October 18, 2025
Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cellsArianna Bandini, Letizia Biso, Cristina Viaggi, et al.
Pageof 372